Galapagos FIRST LOOK: NHL/CLL CAR-T data at ASH 2023 shows continued benefit
Galapagos presented updated data from the phase 1/2 CAR-T trials in r/r NHL and r/r CLL at ASH 2023, which continued to show benefit in a larger set of patients. We look forward to additional data updates in 2024 as well as the start of the pivotal r/r CLL trial expected in 2H24. We reiterate our Accumulate rating and €55 TP. We reiterate our Accumulate rating and €55.Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, addressing disease areas of high unmet medical need. Execution on its proprietary drug target discovery platform has delivered a pipeline that consists of three Phase 2, three Phase 1, five pre-clinical, and 20 discovery programs in inflammation, cystic fibrosis, or CF, osteoarthritis, and other indications. Co.'s highly flexible platform offers applicability across a broad set of therapeutic areas. Co.'s programs include filgotinib, GLPG1837, GLPG1690, GLPG2222, GLPG1972.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.